BriaCell Therapeutics Corp. (BCT) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

7.77 k

Shareholding (Jan 2025)

FII

2.80%

Held by 42 FIIs

DII

97.2%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 36 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.00

Return on Equity

-154.52%

Price to Book

1.46

Revenue and Profits:

Net Sales:

(Quarterly Results - Apr 2025)

Net Profit:

-9 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

138.21%

6 Months

106.92%

1 Year

32.56%

2 Years

-31.16%

3 Years

-52.59%

4 Years

-60.6%

5 Years

-73.01%

BriaCell Therapeutics Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-230.46%

EBIT to Interest (avg)

-18.00

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

1.42%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.81

EV to EBIT

-0.41

EV to EBITDA

-0.41

EV to Capital Employed

-13.87

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-200.30%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bullish

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jan 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 42 Foreign Institutions (2.8%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Apr 2025 is -482.61% vs 134.85% in Apr 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.00",
          "val2": "-12.50",
          "chgp": "28.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "14.90",
          "chgp": "-98.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.80",
          "val2": "2.30",
          "chgp": "-482.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jul'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jul 2024 is 0.00% vs 0.00% in Jul 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jul 2024 is 75.37% vs 20.23% in Jul 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jul'24",
        "Jul'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-45.20",
          "val2": "-31.20",
          "chgp": "-44.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "38.40",
          "val2": "2.80",
          "chgp": "1,271.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.70",
          "val2": "-27.20",
          "chgp": "75.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Apr'25 - YoY

Apr'25

Apr'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.00

-12.50

28.00%

Interest

0.10

0.00

Exceptional Items

0.20

14.90

-98.66%

Consolidate Net Profit

-8.80

2.30

-482.61%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Apr 2024

Consolidated Net Profit

YoY Growth in quarter ended Apr 2025 is -482.61% vs 134.85% in Apr 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jul'24

Jul'24

Jul'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-45.20

-31.20

-44.87%

Interest

0.00

Exceptional Items

38.40

2.80

1,271.43%

Consolidate Net Profit

-6.70

-27.20

75.37%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jul 2024 is 0.00% vs 0.00% in Jul 2023

Consolidated Net Profit

YoY Growth in year ended Jul 2024 is 75.37% vs 20.23% in Jul 2023

All Annual Results

Company CV

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

Pharmaceuticals & Biotechnology

BriaCell Therapeutics Corp. is a Canada-based immuno-oncology focused biotechnology company developing targeted approaches for the management of cancer. The Company, in collaboration with Incyte Corporation, is conducting a Phase I/IIa clinical trial of Bria-IMT in combination with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and manufacturing logistics associated with other personalized immunotherapies.

Company Coordinates

Company Details

Bellevue Centre, 235 15th St 3rd Floor , WEST VANCOUVER BC : V7T 2X1

Tel: 1 604 9211810

http://www.briacell.com/

Registrar Details